- Home
- EPRT vs RYTM Comparison
EPRT vs RYTM Comparison
Compare EPRT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EPRT | RYTM |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.4B |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | EPRT | RYTM |
|---|---|---|
| Price | $30.91 | $105.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $35.27 | ★ $129.92 |
| AVG Volume (30 Days) | ★ 1.8M | 654.5K |
| Earning Date | 02-11-2026 | 02-25-2026 |
| Dividend Yield | ★ 3.99% | N/A |
| EPS Growth | ★ 8.17 | N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $531,061,000.00 | $174,334,000.00 |
| Revenue This Year | $24.48 | $47.40 |
| Revenue Next Year | $17.26 | $56.14 |
| P/E Ratio | $24.99 | ★ N/A |
| Revenue Growth | 23.93 | ★ 54.92 |
| 52 Week Low | $27.44 | $45.91 |
| 52 Week High | $33.35 | $122.20 |
Technical Indicators
Market Signals| Indicator | EPRT | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 60.15 | 49.28 |
| Support Level | $30.26 | $99.50 |
| Resistance Level | $30.29 | $114.00 |
| Average True Range (ATR) | 0.58 | 5.06 |
| MACD | 0.17 | -0.08 |
| Stochastic Oscillator | 86.93 | 51.12 |
Price Performance
Historical ComparisonAbout EPRT Essential Properties Realty Trust Inc.
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.